2026-09-20T22:02:04Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1113152022-02-01T17:58:36Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Andrew W. Lo.
Kim, Esther S
Technology and Policy Program.
Massachusetts Institute of Technology. Engineering Systems Division
Massachusetts Institute of Technology. Institute for Data, Systems, and Society
Technology and Policy Program
2017-09-15T15:28:45Z
2017-09-15T15:28:45Z
2017
2017
http://hdl.handle.net/1721.1/111315
1003289786
Thesis: S.M. in Technology and Policy, Massachusetts Institute of Technology, School of Engineering, Institute for Data, Systems, and Society, Technology and Policy Program, 2017.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 119-125).
Many obstacles contribute to the uncertainty and risk associated with early drug development, leading to the "valley of death" in which promising drug candidates experience difficulties in reaching the market. These challenges have serious consequences for patient populations facing significant unmet medical needs. In this paper, we highlight three models that offer innovative financing mechanisms or new business models for early stage biopharmaceutical assets. Specifically, we evaluate and profile examples of venture philanthropy and academic-industry partnerships as sources of financial capital for early stage assets. In addition, we identify a "one-disease" business model in biotechnology that can mitigate risk and accelerate the translation of biomedical research into novel therapeutics. The three examples highlight the potential for creative mission-driven models to speed up drug development and provide capital in the earliest, and often riskiest, stages of drug development. These models are collaborative and leverage the expertise of the various stakeholders in the process, including patient advocates, private sector drug developers, and academic researchers.
by Esther S. Kim.
S.M. in Technology and Policy
125 pages
eng
Massachusetts Institute of Technology
MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
http://dspace.mit.edu/handle/1721.1/7582
Institute for Data, Systems, and Society.
Engineering Systems Division.
Technology and Policy Program.
New financing and business models to accelerate the development of novel therapeutics
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="ecf507a3-61a7-42f2-b3f6-a3f16eb3d89d">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>New financing and business models to accelerate the development of novel therapeutics</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2017</PublicationDate>
<Authors>
<Author>
<DisplayName>Kim, Esther S</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Institute for Data, Systems, and Society.</Keyword>
<Keyword>Engineering Systems Division.</Keyword>
<Keyword>Technology and Policy Program.</Keyword>
<Abstract>Many obstacles contribute to the uncertainty and risk associated with early drug development, leading to the "valley of death" in which promising drug candidates experience difficulties in reaching the market. These challenges have serious consequences for patient populations facing significant unmet medical needs. In this paper, we highlight three models that offer innovative financing mechanisms or new business models for early stage biopharmaceutical assets. Specifically, we evaluate and profile examples of venture philanthropy and academic-industry partnerships as sources of financial capital for early stage assets. In addition, we identify a "one-disease" business model in biotechnology that can mitigate risk and accelerate the translation of biomedical research into novel therapeutics. The three examples highlight the potential for creative mission-driven models to speed up drug development and provide capital in the earliest, and often riskiest, stages of drug development. These models are collaborative and leverage the expertise of the various stakeholders in the process, including patient advocates, private sector drug developers, and academic researchers.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>